# US 10,947,297 B2 · Fibronectin based scaffold domain proteins that bind PCSK9

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,947,297 B2
- Document ID: US10947297B2
- Status: Granted
- Kind: B2
- Application number: 15/819,925
- Filed: 2017-11-21
- Published: 2018-07-19
- Granted: 2021-03-16
- Earliest claimed: 2010-04-13
- Assignees: Bristol-Myers Squibb Company
- Applicants: Bristol-Myers Squibb Company
- Inventors: Ray Camphausen; Jonathan H. Davis; Sharon T. Cload; Fabienne M. Denhez; Amna Saeed-Kothe; Dasa Lipovsek; Ching-Hsiung Frederick Lo; Chee Meng Low; Bowman Miao; Tracy S. Mitchell; Rex A. Parker; Ginger C. Rakestraw; Katie A. Russo; Doree F. Sitkoff
- Web page: https://patentgrep.com/patent/US10947297B2

## CPC

- C07K 14/78: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
- A61K 38/39: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- A61K 47/549: {Sugars, nucleosides, nucleotides or nucleic acids}
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/18: against material from animals or humans
- C07K 16/40: against enzymes
- C12N 9/6424: {Serine endopeptidases (3.4.21)}
- C07K 2318/20: Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/31: fusions, other than Fc, for prolonged plasma life, e.g. albumin
- C07K 2319/70: containing domain for protein-protein interaction
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.

## Claims

### Claim 1

A polypeptide comprising a fibronectin type III tenth domain (10Fn3) wherein the 10Fn3 has a BC, DE and FG loop, and
wherein the BC loop comprises the sequence (X1)zX2G where X1 is any amino acid, Z is from 6 to 9, and X2 is Y or H, and the BC loop is selected from:
BC Loop
SEQ ID NO
SWPPPSHGYG
2
SWRPPIHAYG
3
SWDAPIHAYG
4
SWDAPAHAYG
5
SWDAPAVTYG
6
SWSPPANGYG
7
SWTPPPKGYG
8
SWRPPSHAYG
9
SWDPPSHAYG
10
SWEPPSHAYG
11
SWSPPSHAYG
12
SWRPPSNGHG
13
SWVPPSDDYG
14
SWVPSSHAYG
15
SWDPSSHAYG
16
SWEPSSHAYG
17
SWDAPADGGYG
107
SWDAPAGDGYG
108
SWAAPAGGGYG
109
SWDAPADAYG
110
SWDAPADGAYG
111
SWDAPAEGYG
112
SWDAPADEAYG
113
SWDAPADGYG
114
SWDAPAGGGYG
115
SWDAPAADAYG
116
SWDAPAEAGKHYG
117
SWDAPAEAYG
118
SWDAPAAAYG
119
SWDAPAGGYG
120
SWDAPAAGGYG
121
SWDAPAAGYG
122
SWDAPAGAASYG
123
SWDAPAGAYG
124
SWDPPAEGYG
125
SWNPPDVNYG
126
SWDAPAEGGYG
127
SWDAPAEAEAYG
131
SWDAPAEGAYG
132
SWQPPAVTYG
133
SWDPPAGAYG
134
SWAPPSDAYG
135
SWDPPSDDYG
301
SWDAPADDYG
302
SWDAPSDDYG
303,
wherein the DE loop comprises the sequence X1X1X1X3 where X1 is any amino acid and X3 is G or S, and the DE loop is selected from:
DE Loop
SEQ ID NO
PPGKGT
18
PIVEGT
19
PGSEGT
20
PGSKGT
21
PGSKST
22
PVGRGT
23
PVGEGT
24
PIGKGT
25
PVNEGT
26
PVGVGT
27
PSSKGT
136
PVSKST
137
PVSKGT
138
PVFKGT
139
PVYKGT
140
PGYKGT
141,
wherein the FG loop comprises the sequence EX4X1X5X1X1X6GYX4HR (SEQ ID NO: 451) where X1 is any amino acid, X4 is Y or F, X5 is Y, F, or W, and X6 is S or A, and the FG loop is selected from:
FG loop
SEQ ID NO
EYPYKHSGYYHRP
28
EYTFKHSGYYHRP
29
EYTYKGSGYYHRP
30
EYTYNGAGYYHRP
31
EYTYIGAGYYHRP
32
EYTYEGAGYYHRP
33
EYAYNGAGYYHRP
34
EYPWKGSGYYHRP
35
EFPFKWSGYYHRP
36
EFPWPHAGYYHRP
37
EYAFEGAGYYHRP
38
EYPYDYSGYYHRP
142
EYPYEHSGYYHRP
143
EYPYPHSGYYHRP
144
EYTFPGAGYYHRP
145
EYPYDHSGYYHRP
146
EFPYDHSGYYHRP
147
EFPYAHSGYYHRP
148
EFTFPGAGYYHRP
149
EYPYAHSGYFHRP
150
EYDFPGAGYYHRP
151
EYDFPGSGYYHRP
152
EFDYPGSGYYHRP
153
EYSFPGAGYYHRP
154
EFDFPGSGYYHRP
155
EFDFPGAGYYHRP
156
EFPFPGSGYYHRP
157
EFNFPGAGYYHRP
158
EFTYPGSGYYHRP
159
EFPFPGAGYYHRP
160
EFNFPGSGYYHRP
161
EYPYAHAGYYHRP
162
EYPYPFSGYYHRP
163
EYNFIGAGYYHRP
164
EFPYPFAGYYHRP
165
EYTYEHSGYYHRP
166
EFDFVGAGYYHRP
167
EYDFAGSGYYHRP
168
EFAFPGAGYYHRP
169
EYVFPGAGYYHRP
170
EYPYPFAGYYHRP
171
EYPYSHAGYYHRP
172
wherein the polypeptide comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 209, wherein the His6 tag of SEQ ID NO: 209 is deleted, and
wherein the polypeptide binds proprotein convertase subtilisin kexin type 9 (PCSK9).

### Claim 2 (depends on 1)

The polypeptide of claim 1, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 209; wherein the amino acid sequence is truncated at the position corresponding to T94 of SEQ ID NO: 1, optionally with a C-terminal extension of one or more E or D residues.

### Claim 3 (depends on 1)

The polypeptide of claim 1, wherein the polypeptide comprises an amino acid sequence truncated at the position corresponding to T94 of SEQ ID NO: 1, with a C-terminal extension of one or more E or D residues.

### Claim 4 (depends on 1)

The polypeptide of claim 1, wherein the polypeptide binds PCSK9 with a KD of less than 500 nM.

### Claim 5 (depends on 1)

The polypeptide of claim 1, wherein the polypeptide binds PCSK9 with a KD of less than 10 nM.

### Claim 6 (depends on 1)

The polypeptide of claim 1, wherein the polypeptide further comprises one or more pharmacokinetic (PK) moieties selected from polyethylene glycol, sialic acid, Fc, Fc fragment, transferrin, serum albumin, a serum albumin binding protein, and a serum immunoglobulin binding protein.

### Claim 7 (depends on 1)

The polypeptide of claim 1, wherein the polypeptide comprises a serum albumin PK moiety.

### Claim 8 (depends on 1)

A pharmaceutical composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier.

### Claim 9 (depends on 8)

The composition of claim 8, wherein the polypeptide comprises an amino acid sequence truncated at the position corresponding to T94 of SEQ ID NO: 1, with a C-terminal extension of one or more E or D residues.

### Claim 10 (depends on 8)

The composition of claim 8, wherein the polypeptide comprises a serum albumin PK moiety.

### Claim 11 (depends on 1)

The polypeptide of claim 1, wherein the polypeptide binds human proprotein convertase subtilisin kexin type 9 (PCSK9).

### Claim 12 (depends on 1)

The polypeptide of claim 1, wherein the polypeptide comprises an amino acid sequence that is at least 95% identical to SEQ ID NO: 209.

### Claim 13 (depends on 8)

A method of treating hypercholesterolemia in a subject comprising administering to the subject the composition of claim 8.

### Claim 14 (depends on 13)

The method of claim 13, wherein the subject has atherosclerosis.

### Claim 15 (depends on 13)

The method of claim 13, wherein the composition is administered by subcutaneous administration.

### Claim 16 (depends on 13)

The method of claim 13, wherein the composition is administered by intravenous administration.

### Claim 17 (depends on 16)

The method of claim 16, wherein the intravenous administration is by a bolus.

### Claim 18 (depends on 16)

The method of claim 16, wherein the intravenous administration is by continuous infusion.

### Claim 19 (depends on 14)

The method of claim 14, wherein the polypeptide comprises a serum albumin PK moiety.
